Next generation of immunotherapies presented by Chief Scientific Officer Eric Vivier in a meet-the-expert session at AACR 2018 New preclinical data further support ongoing clinical trials with...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events: H.C. Wainwright Global Life Sciences Conference – Monaco...

Additional expansion cohorts to explore the safety and efficacy of monalizumab in combination with durvalumab and standard of care in patients with 1 st - and 2 nd line, metastatic colorectal cancer...

First clinical activity data of the combination of monalizumab and cetuximab New preclinical data further supporting the rationale of Innate’s first- or best-in-class antibodies Eric Vivier, Chief...

Innate Pharma presents a clinical update on its broad and diverse development portfolio of first- or best-in-class antibodies in immuno-oncology Update on the development program with AstraZeneca on...

Cash, cash equivalents and financial assets* amounted to €176.6m (million euros) as of December 31, 2017 Revenue and other income amounted to €44.0m (€65.7m in 2016, including a €13.8m milestone...

Innate Pharma and MedImmune will evaluate the combination of Innate Pharma’s first-in-class IPH5401 antibody and Imfinzi ® (durvalumab) in a Phase I/II study for patients with selected solid tumors...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that Prof. Jean-Yves Blay has been appointed to the Innate Pharma Supervisory Board. Prof. Blay brings significant...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that Professor Eric Vivier has joined the Company as Chief Scientific Officer (CSO) and Senior Vice President...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...